Dual inhibition of TYK2 and PD-L1 boosts immune response in triple negative breast cancer.

Anticancer Drugs · 2025 · PMC11884794 · PMID 39774369

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Deucravacitinib showed a trend towards reducing the proportion of these cell subsets, but it was not significant.

also in 53,322 other papers

an increasing trendno p-value reported

In the 4T1 model, we observed that the expression levels of genes related to antitumor immunity, such as H2-Ab1 , Cd74 , and H2-Eb1 , were significantly increased or showed an increasing trend with INCB086550 alone, while the impact of Deucravacitinib on these genes was not apparent.

also in 63,971 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.